Broncus Holding Corporation (HKG:2216)

Market Cap	321.52M -80.5%
Revenue (ttm)	1.35M -97.9%
Net Income	-139.13M
EPS	-0.29
Shares Out	527.08M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	429,000
Open	0.6100
Previous Close	0.6100
Day's Range	0.5850 - 0.6800
52-Week Range	0.5300 - 3.7200
Beta	1.19
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About Broncus Holding

Broncus Holding Corporation, a medical device company, focuses on the development and commercialization of interventional pulmonology medical devices in China and internationally. The company offers InterVapor, a thermal vapor treatment system to treat chronic obstructive pulmonary disease (COPD); BroncAblate Radiofrequency Ablation System, a transbronchial interventional treatment product for lung cancer; BroncTarget Targeted Lung Denervation (TLD) Radiofrequency Ablation System for the treatment of acute COPD exacerbation management; H-Marker...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2012
• Employees: 191
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2216

Financial Performance

In 2025, Broncus Holding's revenue was $174,000, a decrease of -97.86% compared to the previous year's $8.13 million. Losses were -$17.88 million, 16.8% more than in 2024.

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 3, 2026

Data Sources Report a data error